💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

ESSA Pharma receives $1.2M payment from CPRIT for EPI-506 development costs

Published 04/05/2017, 10:30 AM
© Reuters.  ESSA Pharma receives $1.2M payment from CPRIT for EPI-506 development costs
EPI
-
  • As part of the $12M grant awarded in July 2014, ESSA Pharma (EPIX) receives $1.2M from the Cancer Prevention Research Institute of Texas (CPRIT) for costs associated with the ongoing Phase 1 dose escalation study of prostate cancer candidate EPI-506 and preparations for the Phase 2 dose expansion trial expected to start later this year. It is eligible to receive an additional ~$229K after completing certain filings with CPRIT.
  • EPI-506 targets a specific part of the androgen receptor (AR) called the N-terminal domain. The company says this novel target enables EPI-506 to overcome AR's resistance mechanisms.
  • Previously: ESSA Pharma receives $4M under grant from Texas cancer research organization (Jan. 30)


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.